Kymera Therapeutics

MA - WatertownBiotechnology2 H-1B visas (FY2023)

Focus: Kymera Therapeutics is a biotech company specializing in targeted protein degradation (TPD) using small molecules, headquartered in Watertown, MA. The company operates in early-stage development across immunology, respiratory, and oncology indications.

Biotechnology Immunology Unknown Targeted Protein Degradation

Profile data last refreshed 20h ago · AI intelligence enriched 2w ago

Open Jobs

About Kymera Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Kymera Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

12 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atop

Hidradenitis Suppurativa

N/A

Clinical Trials (1)

NCT04440410Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis

N/A

Help build intelligence for Kymera Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge TPD platform technology with potential to redefine protein degradation therapeutics across multiple disease areas
Broad therapeutic pipeline spanning 12 active programs across immunology (atopic dermatitis, eosinophilic asthma), oncology (NHL, myeloid malignancies), and dermatology
Early-stage visibility: 7 Phase 1 and 2 Phase 2 programs provide multiple near-term clinical catalysts and learning opportunities

Watch Out For

Pre-revenue company with no approved products; financial sustainability and funding runway are critical unknowns given missing financial data
Very early pipeline maturity (zero Phase 3 programs) creates execution risk and extended timeline to value inflection; limited near-term de-risking catalysts

Generated by Claude from Kymera Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

KT-333

Non Hodgkin Lymphoma (NHL)

Phase 1

Clinical Trials (1)

NCT05225584Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Phase 1

KT-621

Atopic Dermatitis

Phase 1

Clinical Trials (1)

NCT06945458Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

Phase 1

KT-253

Myeloid Malignancies

Phase 1

Clinical Trials (1)

NCT05775406Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

Phase 1

KT-413

Non Hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT05233033Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

Phase 1

KT-621

Healthy Participants Study

Phase 1

Clinical Trials (1)

NCT06673667First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

Phase 1

KT-474/Placebo

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT04772885A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Phase 1

KT-579

Healthy Participants

Phase 1

Clinical Trials (1)

NCT07412288First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

Phase 1

SAR444656

Hidradenitis Suppurativa

Phase 2

Clinical Trials (1)

NCT06028230A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 2

KT-621

Eosinophilic Asthma

Phase 2

Clinical Trials (1)

NCT07323654A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Phase 2

SAR444656

Atopic Dermatitis

Phase 2

Clinical Trials (1)

NCT06058156Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis